Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript March 5, 2026
Atea Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.57 EPS, expectations were $-0.49.
Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals’ Fourth Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] I would now like to turn the call over to Jonae Barnes, Senior Vice President of Investor Relations and Corporate...
